Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- STATISTICS／Population Declines for Second Year in a Row in 2006: Korosho
January 22, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 22, 2007
- Meiji Seika to Focus on Infectious Diseases, CNS, Generics
January 22, 2007
- Nippon Kayaku Focusing on R&D of Micelle-related Technology
January 22, 2007
- BUSINESS NEWS IN BRIEF
January 22, 2007
- Burgeoning Market for ARBs -Hot Battlefield for Megapharmas-Part 2
January 22, 2007
- Interest Growing in Exploratory Early Clinical Trials
January 22, 2007
- Preparation for Vaccine Development Project to Begin This Year: NIBIO
January 22, 2007
- Toyama to Focus on Development of T-705 as Anti-Flu Drug
January 22, 2007
- R&D NEWS IN BRIEF
January 22, 2007
- TOPICS／Milder Pollinosis Season Expected This Year↓
January 22, 2007
- SEMIANR
January 22, 2007
- PMDA to Start 2nd 5-Year Plan a Year Ahead of Schedule
January 22, 2007
- JGPMA Proposes New Drug Benefit System
January 22, 2007
- Reform of Review System a Top Priority for PFSB: Mr Takahashi
January 22, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2007
- JPMA to Propose New NHI Pricing System with Innovation as Key Word
January 22, 2007
- Original Makers, GE Makers Must Cooperate in Case of Shortage: Taiyo Yakuhin
January 22, 2007
- JPA Concerned about Effects of Flat Sum System on Dispensing Services
January 22, 2007
- Kodak to Sell Health Group to Onex
January 22, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…